RARE PHOTOS: 12 | Vintage Vibes

AstraZeneca in talks over £300bn mega-merger with US rival – reports

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

Evening Standard · Aug 3

AstraZeneca falls to third-largest UK company amid US merger talks

Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale

The Guardian - UK · Aug 3

AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.

MarketBeat · Aug 2

Public Comment Closes on the FDA Plan to Permanently Bar Bulk Compounding of Semaglutide and Tirzepatide

The comment window on FDA's proposal to keep semaglutide and tirzepatide off the 503B bulk list closed July 30. No final decision has been announced.

Medical Daily · Jul 31

Courts Keep Striking Down State Laws Aimed at Pharmacy Middlemen, and Independent Drugstores Are Watching

States keep passing laws to rein in pharmacy benefit managers, and courts keep blocking them. What it means for where you fill prescriptions.

Medical Daily · Jul 30

Active U.S. Drug Shortages Have Risen to 223, and Two Official Counts Disagree on the Scale

Pharmacists count 223 active US drug shortages while the FDA tracks far fewer. Here is why the two numbers differ and what it means for patients.

Medical Daily · Jul 30

India takes action against 90% of inspected high-risk pharmaceutical facilities, regulator says

Amid increasing global concerns over Indian pharmaceuticals, India's drug regulator is rigorously addressing high-risk manufacturing sites. This decisive action follows extensive inspections -- over 960 since late last year -- triggered by tragic child fatalities linked to these drugs. By December 31, manufacturers must adhere to World Health Organization standards.

The Economic Times · Jul 30

Judge Says the FDA Never Explained Why Mifepristone Prescriber Certification Was Necessary

A federal judge ruled the FDA failed to justify its 2023 mifepristone REMS requirements. The rules stay in effect while the agency reconsiders.

Medical Daily · Jul 30

ChrysCapital acquires controlling 70.68% stake in Novartis' India listed unit in first majority pharma investment

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics…

The Economic Times · Jul 30

Medicare to End Premium Stabilization Program for Standalone Drug Plans

CMS is ending the Part D Premium Stabilization Demonstration after 2026. Here is what it did and what seniors will learn in September.

Medical Daily · Jul 29